{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:44:32Z","timestamp":1790837072297,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T00:00:00Z","timestamp":1713484800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["21597-2019072415413447 v2"],"award-info":[{"award-number":["21597-2019072415413447 v2"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.rpth.2024.102426","type":"journal-article","created":{"date-parts":[[2024,4,27]],"date-time":"2024-04-27T01:10:04Z","timestamp":1714180204000},"page":"102426","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["A small-molecule hemostatic agent for the reversal of direct oral anticoagulant\u2013induced bleeding"],"prefix":"10.1016","volume":"8","author":[{"given":"Maximilien","family":"Desvages","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Borgel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Adam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ge","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Jaouen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christelle","family":"Reperant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile V.","family":"Denis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Desma\u00eble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1370-5312","authenticated-orcid":false,"given":"Elsa P.","family":"Bianchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpth.2024.102426_bib1","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jacc.2019.01.011","volume":"74","author":"January","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.rpth.2024.102426_bib2","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.rpth.2024.102426_bib3","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rpth.2024.102426_bib4","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1161\/CIRCULATIONAHA.121.056355","article-title":"Direct oral anticoagulants versus warfarin in patients with atrial fibrillation: patient-level network meta-analyses of randomized clinical trials with interaction testing by age and sex","volume":"145","author":"Carnicelli","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.rpth.2024.102426_bib5","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1016\/j.jacc.2014.02.549","article-title":"Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: the ARISTOTLE Trial (apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation): predictors, characteristics, and clinical outcomes","volume":"63","author":"Hylek","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.rpth.2024.102426_bib6","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1161\/CIRCULATIONAHA.110.004747","article-title":"Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial","volume":"123","author":"Eikelboom","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.rpth.2024.102426_bib7","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1182\/hematology.2019000072","article-title":"What we have learned about direct oral anticoagulant reversal","volume":"2019","author":"Siegal","year":"2019","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.rpth.2024.102426_bib8","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1016\/j.ajem.2012.02.012","article-title":"Therapy and outcomes in massive pulmonary embolism from the Emergency Medicine Pulmonary Embolism in the Real World Registry","volume":"30","author":"Lin","year":"2012","journal-title":"Am J Emerg Med"},{"key":"10.1016\/j.rpth.2024.102426_bib9","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nm.3102","article-title":"A\u00a0specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa","volume":"19","author":"Lu","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.rpth.2024.102426_bib10","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s40265-018-0940-4","article-title":"Andexanet\u00a0alfa: first global approval","volume":"78","author":"Heo","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.rpth.2024.102426_bib11","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.10079","article-title":"Availability of specific direct oral anticoagulant reversal agents in US hospitals","volume":"4","author":"Kanjee","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"Suppl 1","key":"10.1016\/j.rpth.2024.102426_bib12","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1182\/blood.V130.Suppl_1.629.629","article-title":"Effect of andexanet-TFPI interaction on in\u00a0vitro thrombin formation and coagulation markers in the TF-pathway","volume":"130","author":"Lu","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102426_bib13","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1056\/NEJMoa1814051","article-title":"Full study report of andexanet\u00a0alfa for bleeding associated with factor Xa inhibitors","volume":"380","author":"Connolly","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rpth.2024.102426_bib14","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.annemergmed.2019.12.026","article-title":"Is it truly \u201calpha\u201d? incidence of thrombotic events with andexanet\u00a0alfa at a single academic medical center","volume":"75","author":"Parsels","year":"2020","journal-title":"Ann Emerg Med"},{"key":"10.1016\/j.rpth.2024.102426_bib15","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.40145","article-title":"Evaluation of direct oral anticoagulant reversal agents in intracranial hemorrhage: a systematic review and meta-analysis","volume":"5","author":"Chaudhary","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.rpth.2024.102426_bib16","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1016\/j.ajem.2020.08.019","article-title":"Emergent reversal of oral factor Xa inhibitors with four-factor prothrombin complex concentrate","volume":"38","author":"Lipari","year":"2020","journal-title":"Am J Emerg Med"},{"key":"10.1016\/j.rpth.2024.102426_bib18","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1160\/TH15-12-0927","article-title":"Inactivated antithrombins as fondaparinux antidotes: a promising alternative to haemostatic agents as assessed in\u00a0vitro in a thrombin-generation assay","volume":"116","author":"Bourti","year":"2016","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102426_bib19","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.1182\/bloodadvances.2020001699","article-title":"An engineered factor Va prevents bleeding induced by direct-acting oral anticoagulants by different mechanisms","volume":"4","author":"von Drygalski","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2024.102426_bib20","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1021\/jm990467o","article-title":"Structure-activity relationships and binding mode of styrylquinolines as potent inhibitors of HIV-1 integrase and replication of HIV-1 in cell culture","volume":"43","author":"Zouhiri","year":"2000","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.rpth.2024.102426_bib21","doi-asserted-by":"crossref","first-page":"878","DOI":"10.3390\/12040878","article-title":"How many drugs are catecholics","volume":"12","author":"Yang","year":"2007","journal-title":"Molecules"},{"key":"10.1016\/j.rpth.2024.102426_bib22","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-93372-9","article-title":"Apixaban concentration variability and relation to clinical outcomes in real-life patients with atrial fibrillation","volume":"11","author":"Mavri","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.rpth.2024.102426_bib23","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1055\/a-1450-8178","article-title":"2021 Update of the International Council for Standardization in Haematology recommendations for laboratory measurement of direct oral anticoagulants","volume":"121","author":"Douxfils","year":"2021","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102426_bib24","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1080\/17460441.2019.1654453","article-title":"Dealing with frequent hitters in drug discovery: a multidisciplinary view on the issue of filtering compounds on biological screenings","volume":"14","author":"Dantas","year":"2019","journal-title":"Expert Opin Drug Discov"},{"key":"10.1016\/j.rpth.2024.102426_bib25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0064100","article-title":"Thrombin generation capacity of prothrombin complex concentrate in an in\u00a0vitro dilutional model","volume":"8","author":"Grottke","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.rpth.2024.102426_bib26","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.bja.2018.05.063","article-title":"Factor IX from prothrombin complex concentrate augments low dose tissue factor-triggered thrombin generation in\u00a0vitro","volume":"121","author":"Hasan","year":"2018","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.rpth.2024.102426_bib27","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12959-020-00228-9","article-title":"Reversal of rivaroxaban anticoagulant effect by prothrombin complex concentrates: which dose is sufficient to restore normal thrombin generation?","volume":"18","author":"Giffard-Quillon","year":"2020","journal-title":"Thromb J"},{"key":"10.1016\/j.rpth.2024.102426_bib28","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s40560-018-0303-y","article-title":"Safety of 4-factor prothrombin complex concentrate (4F-PCC) for emergent reversal of factor Xa inhibitors","volume":"6","author":"Tao","year":"2018","journal-title":"J\u00a0Intensive Care"},{"key":"10.1016\/j.rpth.2024.102426_bib29","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.annemergmed.2019.09.001","article-title":"Anticoagulant reversal strategies in the emergency department setting: recommendations of a multidisciplinary expert panel","volume":"76","author":"Baugh","year":"2020","journal-title":"Ann Emerg Med"},{"key":"10.1016\/j.rpth.2024.102426_bib30","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1080\/17474086.2020.1716726","article-title":"The cost of hemophilia treatment: the importance of minimizing it without detriment to its quality","volume":"13","author":"Rodriguez-Merchan","year":"2020","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.rpth.2024.102426_bib31","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/bjh.18379","article-title":"Current and future therapies for haemophilia\u2014beyond factor replacement therapies","volume":"200","author":"Nogami","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.rpth.2024.102426_bib32","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1016\/j.xphs.2023.05.014","article-title":"Immunogenicity of therapeutic biological modalities - lessons from hemophilia A therapies","volume":"112","author":"Nguyen","year":"2023","journal-title":"J\u00a0Pharm Sci"},{"key":"10.1016\/j.rpth.2024.102426_bib33","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1136\/jramc-2018-001066","article-title":"Systematic review of prehospital haemostatic dressings","volume":"166","author":"Welch","year":"2020","journal-title":"BMJ Mil Health"},{"key":"10.1016\/j.rpth.2024.102426_bib34","doi-asserted-by":"crossref","first-page":"63","DOI":"10.7205\/MILMED.170.1.63","article-title":"Hemorrhage control in the battlefield: role of new hemostatic agents","volume":"170","author":"Alam","year":"2005","journal-title":"Mil Med"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037924001158?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037924001158?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,28]],"date-time":"2024-07-28T05:32:51Z","timestamp":1722144771000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037924001158"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S2475037924001158"],"URL":"https:\/\/doi.org\/10.1016\/j.rpth.2024.102426","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A small-molecule hemostatic agent for the reversal of direct oral anticoagulant\u2013induced bleeding","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpth.2024.102426","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}],"article-number":"102426"}}